You can order a viral vector the way you order a reagent. Send a construct, choose a scale, get a vial back, and move on. Sometimes, that’s exactly what you need. But many programs that run into trouble don’t encounter problems when the vial arrives. They encounter them three months later, when the titer doesn’t support the intended dose, transduction efficiency in the target cells doesn’t match expectations, or a reviewer asks for characterization data that was never generated.
The difference between a vendor and a partner is where the conversation happens. A vendor talks to you when you place the order and when the product is delivered. A partner talks to you before the construct is finalized and after the data comes back.
Before the Run: The Construct Conversation
Many of the factors that determine whether a vector batch meets expectations are established before production begins. The construct is one of them.
Here are a few things worth discussing early:
Payload size. AAV has a limited packaging capacity. Constructs approaching that limit can present challenges for production, packaging efficiency and genome integrity. If the transgene, promoter and regulatory elements are pushing the limit, it’s better to identify potential issues before production than after delivery.
Promoter choice. A strong, ubiquitous promoter may be appropriate, but it isn’t always the best choice. If your application requires tissue-specific expression or a particular level of transgene expression, promoter selection should reflect those requirements.
Serotype or pseudotype. This decision should be guided by the target cells, route of delivery and intended application, rather than simply copying the approach used in a previous study. Depending on the program, testing more than one option at a smaller scale may be worthwhile before committing to a larger production run.
Lentivirus versus AAV. The choice depends on the desired expression profile, target cell type and experimental goals. Lentiviral vectors are commonly used when stable integration is needed, while AAV is often used for predominantly episomal gene delivery. The right choice depends on the biology and application, not just what was used previously.
None of this is exotic. It’s a conversation, and it’s much easier to address these questions before production begins.
The Titer You Need, Not Just the Titer You Asked For
Almost every vector request arrives with a titer number attached. Often, it’s a number inherited from a protocol, quoted by a previous supplier or selected because it seemed like a safe target.
The more useful question is the one underneath it: What are you planning to do with this vector?
A mouse study involving 20 animals has specific dosing and volume requirements. A primary-cell transduction at a given multiplicity of infection (MOI) has its own requirements. A series of pilot experiments may be better served by a smaller, well-characterized batch than by a larger batch that sits in a freezer while activity changes over time.
Two distinctions matter here.
Physical titer measures vector-associated material, often reported as vector genome copies per mL for AAV or lentiviral preparations. Functional titer measures the vector’s ability to achieve a defined biological outcome in a specified assay.
These measurements are related, but they are not interchangeable. Their relationship depends on the vector, preparation, assay and target cells.
A quote expressed in genome copies per mL tells you something important, but it doesn’t necessarily tell you how effectively the vector will perform in your intended application.
A good manufacturing partner will ask about your target cells, MOI, number of wells or animals, and experimental goals before working backwards to determine your requirements.
Sometimes, that conversation reveals that you need less material than you initially requested. That can save money without compromising your experimental objectives.
The Data Has to Travel With the Program
A certificate of analysis is not necessarily a complete characterization package.
If your program is progressing toward a grant renewal, partnership, pre-IND meeting or due diligence review, the supporting vector data becomes increasingly important.
Depending on the vector type, intended use and stage of development, useful characterization data may include:
- Functional titer, with the assay and target cell type clearly defined.
- Physical titer and, where appropriate, the relationship between physical and functional measurements.
- For AAV, the full-to-empty capsid ratio.
- Residual host-cell DNA and residual plasmid DNA, where relevant.
- Purity and aggregate content, as appropriate for the product.
- Confirmation of vector identity and genome integrity, using suitable analytical methods.
Not every program requires every test, and the appropriate characterization package depends on the application and development stage.
The goal isn’t to generate paperwork for its own sake. It’s to have the evidence needed to understand your material, interpret your results and support the next stage of your program.
Planning characterization early also helps avoid delays and additional costs when questions arise later, particularly if the original material has already been consumed.
When a Run Underperforms
Sometimes, a batch comes in below expectations. Viral vector production is a biological process, and variability can occur.
This is the moment that reveals what kind of relationship you have with your manufacturer.
A vendor sends the results and the invoice. A partner sends the results, explains what the data may indicate, and works with you to understand what happened.
Was it the construct — a large cassette, a challenging promoter or a sequence-related issue affecting production? Was it the process — transfection efficiency, harvest timing or losses during purification? Or was it the assay — for example, a functional titer measured in a cell line that behaves differently from your target cells?
Each possibility points toward a different next step. Identifying the right one requires more than looking at the final number.
It requires access to relevant process data, a willingness to investigate potential causes and a manufacturer prepared to take responsibility for issues within its control.
The practical test is simple: After a disappointing run, does the next one improve for a reason someone can explain?
Six Questions Worth Asking a Viral Vector Manufacturer
These questions are useful when evaluating any manufacturer, including us.
- Will you review my construct before quoting the project and flag potential concerns?
- Is the titer in your quote physical or functional, and which assay and cell type are used?
- What characterization data is included as standard, and what requires additional testing?
- Who will I work with throughout the project: a scientist familiar with the production run, an account manager, or both?
- If a run underperforms, what process data and troubleshooting support will be available?
- Can you support the program as it scales, or will moving to larger production volumes require requalification with another provider?
The answers matter, but so does how clearly a manufacturer can explain its approach, limitations and responsibilities.
Start With the Conversation
Tailored Genes manufactures lentiviral, AAV and adenoviral vectors and develops stable cell lines in Vaughan, Ontario, supporting academic researchers, biotech startups and pharmaceutical partners.
We believe a successful manufacturing project starts with understanding the construct, the target cells and the goals of the program – before discussing a quote.
If you’re planning a viral vector campaign, book a 30-minute consultation with our founder and Scientific Director, Dr. Chetankumar Tailor, to discuss your project and manufacturing requirements.
Book a consultation: https://calendly.com/tailoredgenesmarketing/30min
Learn more about our services at https://www.tailored-genes.com.
